Proteins and Peptides

23 June 2024

NeuroBo Pharmaceuticals’ DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

23 June 2024

Sun Pharma’s GL0034 (Utreglutide) Demonstrates Significant Weight Loss, Gluco-metabolic and Lipid Lowering Efficacy in Individuals with Obesity in Oral Presentation at the American Diabetes Association 84th Scientific Sessions

21 June 2024

Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide

21 June 2024

First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion

14 June 2024

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

13 June 2024

Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant

11 June 2024

Full-Life Technologies Disclosed Preclinical Data of its NTSR1-targeting RDC Program FL-091 in an Oral Presentation at the 2024 SNMMI Annual Meeting

9 June 2024

Lilly’s tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks

7 June 2024

Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

6 June 2024

Stealth BioTherapeutics Announces First Patient Enrolled in Global Phase 3 Clinical Program for Elamipretide in Patients with Dry Age-Related Macular Degeneration

6 June 2024

Boston Pharmaceuticals Presents Data at EASL Congress 2024 Showing Treatment With Long-acting FGF21 Analogue, BOS-580, Improved Lipid Profiles in Patients with Phenotypic MASH

5 June 2024

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

2 June 2024

Sapience Therapeutics Presents Positive Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024 in Oral Presentation

1 June 2024

Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024

30 May 2024

LIB Therapeutics Announces Positive Lerodalcibep Results from Two Phase 3 LIBerate Studies at the 92nd European Atherosclerosis Society Congress

28 May 2024

selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis

21 May 2024

MTTI Reports on 225Ac-EBTATE and 177Lu-EBTATE Radiopharmaceuticals at 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting

21 May 2024

AT278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase I Clinical Trial in Overweight and Obese People With Type 2 Diabetes

20 May 2024

GC Biopharma/Novel Pharma’s Sanfilippo Syndrome Treatment Obtains FDA IND Approval

18 May 2024

Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants

17 May 2024

First Wave BioPharma Changes Name to Entero Therapeutics

17 May 2024

With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin

17 May 2024

Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity

15 May 2024

FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer

10 May 2024

Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia

9 May 2024

Aspaveli® (pegcetacoplan) approved in Europe for use among treatment naïve adult patients with PNH

2 May 2024

Alpha-9 Oncology Announces First Patient Dosed in Phase 1 Study of A9-3202 in Patients with Locally Advanced or Metastatic Melanoma

2 May 2024

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline

30 April 2024

Enlaza Therapeutics Raises $100 Million through Its Series A Financing, Led by the Life Sciences Group of J.P. Morgan Private Capital

29 April 2024

Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

c-Met-Targeted Antibody Therapy Pipeline Review

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

TSLP Pipeline Review

Adalimumab (Humira) Biosimilars Pipeline Review

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

Ustekinumab (Stelara) Biosimilars Pipeline Review

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review